WO2017011820A3 - Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases - Google Patents

Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases Download PDF

Info

Publication number
WO2017011820A3
WO2017011820A3 PCT/US2016/042680 US2016042680W WO2017011820A3 WO 2017011820 A3 WO2017011820 A3 WO 2017011820A3 US 2016042680 W US2016042680 W US 2016042680W WO 2017011820 A3 WO2017011820 A3 WO 2017011820A3
Authority
WO
WIPO (PCT)
Prior art keywords
interleukin
receptor
peptide inhibitors
inflammatory diseases
treat inflammatory
Prior art date
Application number
PCT/US2016/042680
Other languages
French (fr)
Other versions
WO2017011820A2 (en
Inventor
Gregory BOURNE
Xiaoli Cheng
Brian Troy FREDERICK
Jie Zhang
Dinesh V. Patel
David Liu
Ashok Bhandari
Original Assignee
Protagonist Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/040658 external-priority patent/WO2016011208A1/en
Priority to EA201890325A priority Critical patent/EA035733B9/en
Application filed by Protagonist Therapeutics, Inc. filed Critical Protagonist Therapeutics, Inc.
Priority to EP16825301.1A priority patent/EP3341011A4/en
Priority to AU2016293619A priority patent/AU2016293619B2/en
Priority to CN201680049562.2A priority patent/CN108348580B/en
Priority to BR112018000691A priority patent/BR112018000691A2/en
Priority to JP2018501178A priority patent/JP6858174B2/en
Priority to CR20180029A priority patent/CR20180029A/en
Priority to MX2018000542A priority patent/MX2018000542A/en
Priority to CA2991984A priority patent/CA2991984A1/en
Priority to UAA201801482A priority patent/UA123772C2/en
Priority to US15/745,371 priority patent/US10787490B2/en
Priority to KR1020187004612A priority patent/KR102513978B1/en
Publication of WO2017011820A2 publication Critical patent/WO2017011820A2/en
Publication of WO2017011820A3 publication Critical patent/WO2017011820A3/en
Priority to PH12018500086A priority patent/PH12018500086A1/en
Priority to DO2018000010A priority patent/DOP2018000010A/en
Priority to IL256827A priority patent/IL256827A/en
Priority to NI201800008A priority patent/NI201800008A/en
Priority to CONC2018/0000349A priority patent/CO2018000349A2/en
Priority to ECIEPI20182929A priority patent/ECSP18002929A/en
Priority to SV2018005614A priority patent/SV2018005614A/en
Priority to HK19100122.0A priority patent/HK1257747A1/en
Priority to HK19101174.5A priority patent/HK1259149A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
PCT/US2016/042680 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases WO2017011820A2 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
UAA201801482A UA123772C2 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US15/745,371 US10787490B2 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EP16825301.1A EP3341011A4 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2016293619A AU2016293619B2 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CN201680049562.2A CN108348580B (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
BR112018000691A BR112018000691A2 (en) 2015-07-15 2016-07-15 interleukin-23 receptor peptide inhibitors and their use to treat inflammatory diseases
JP2018501178A JP6858174B2 (en) 2015-07-15 2016-07-15 Peptide inhibitors of the interleukin 23 receptor, and their use for treating inflammatory diseases
CR20180029A CR20180029A (en) 2015-07-15 2016-07-15 POTENTIAL INHIBITORS OF THE INTERLEUCINE RECEIVER 23 AND ITS USE TO TREAT INFLAMMATORY DISEASES
MX2018000542A MX2018000542A (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases.
CA2991984A CA2991984A1 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
KR1020187004612A KR102513978B1 (en) 2015-07-15 2016-07-15 Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases
EA201890325A EA035733B9 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
PH12018500086A PH12018500086A1 (en) 2015-07-15 2018-01-09 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
DO2018000010A DOP2018000010A (en) 2015-07-15 2018-01-10 PEPTIDE INHIBITORS OF THE INTERLEUCINE RECEIVER 23 AND ITS USE TO TREAT INFLAMMATORY DISEASES
IL256827A IL256827A (en) 2015-07-15 2018-01-10 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
NI201800008A NI201800008A (en) 2015-07-15 2018-01-11 INTERLEUKIN 23 RECEPTOR PEPTIDIC INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES
CONC2018/0000349A CO2018000349A2 (en) 2015-07-15 2018-01-15 Interleukin receptor peptide inhibitors 23
ECIEPI20182929A ECSP18002929A (en) 2015-07-15 2018-01-15 INTERLEUKIN 23 RECEPTOR PEPTIDIC INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES
SV2018005614A SV2018005614A (en) 2015-07-15 2018-01-15 PEPTIDIC INHIBITORS OF INTERLEUCINE RECEIVER 23 AND USE TO TREAT INFLAMMATORY DISEASES
HK19100122.0A HK1257747A1 (en) 2015-07-15 2019-01-04 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
HK19101174.5A HK1259149A1 (en) 2015-07-15 2019-01-23 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US14/800,627 2015-07-15
PCT/US2015/040658 WO2016011208A1 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US14/800,627 US9624268B2 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
USPCT/US15/40658 2015-07-15
US201562264820P 2015-12-08 2015-12-08
US62/264,820 2015-12-08
US201662281123P 2016-01-20 2016-01-20
US62/281,123 2016-01-20

Publications (2)

Publication Number Publication Date
WO2017011820A2 WO2017011820A2 (en) 2017-01-19
WO2017011820A3 true WO2017011820A3 (en) 2017-02-23

Family

ID=57757647

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/042680 WO2017011820A2 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Country Status (23)

Country Link
EP (1) EP3341011A4 (en)
JP (1) JP6858174B2 (en)
KR (1) KR102513978B1 (en)
CN (1) CN108348580B (en)
AU (1) AU2016293619B2 (en)
BR (1) BR112018000691A2 (en)
CA (1) CA2991984A1 (en)
CL (3) CL2018000128A1 (en)
CO (1) CO2018000349A2 (en)
CR (1) CR20180029A (en)
DO (1) DOP2018000010A (en)
EA (1) EA035733B9 (en)
EC (1) ECSP18002929A (en)
HK (2) HK1257747A1 (en)
IL (1) IL256827A (en)
MX (1) MX2018000542A (en)
NI (1) NI201800008A (en)
PE (1) PE20180571A1 (en)
PH (1) PH12018500086A1 (en)
SG (1) SG10201912066SA (en)
SV (1) SV2018005614A (en)
UA (1) UA123772C2 (en)
WO (1) WO2017011820A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201610416TA (en) 2012-06-13 2017-01-27 Incyte Corp Substituted tricyclic compounds as fgfr inhibitors
HRP20211911T1 (en) 2013-03-15 2022-03-18 Protagonist Therapeutics, Inc. Hepcidin analogues and uses therof
SI2986610T1 (en) 2013-04-19 2018-04-30 Incyte Holdings Corporation Bicyclic heterocycles as fgfr inhibitors
SI3143037T1 (en) 2014-05-16 2021-11-30 Protagonist Therapeutics, Inc. Alpha4beta7 integrin thioether peptide antagonists
CA2955460A1 (en) 2014-07-17 2016-01-21 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP3201217A4 (en) 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
AU2015328002A1 (en) 2014-10-01 2017-04-27 Protagonist Therapeutics, Inc. Novel alpha4beta7 peptide monomer and dimer antagonists
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
MX2020004108A (en) 2015-02-20 2022-01-03 Incyte Corp Bicyclic heterocycles as fgfr inhibitors.
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2017165676A1 (en) 2016-03-23 2017-09-28 Protagonist Therapeutics, Inc. METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS
JP2020505352A (en) * 2017-01-18 2020-02-20 プロタゴニスト セラピューティクス， インコーポレイテッド Peptide inhibitors of the interleukin-23 receptor and their use for treating inflammatory diseases
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
GB2563875B (en) * 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery
CA3073806A1 (en) 2017-09-11 2019-03-14 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
TW201946630A (en) 2018-05-04 2019-12-16 美商英塞特公司 Salts of an FGFR inhibitor
US20200040037A1 (en) * 2018-07-12 2020-02-06 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN110015978B (en) * 2019-04-29 2021-03-19 康化（上海）新药研发有限公司 Synthesis method of O- [2- [ [ (tert-butyloxycarbonyl) amino ] ethyl ] -N- [ fluorenylmethoxycarbonyl ] -L-tyrosine
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3146390A1 (en) * 2019-07-10 2021-01-14 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
IL291901A (en) 2019-10-14 2022-06-01 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP3819307A1 (en) 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
EP4090670A1 (en) 2020-01-15 2022-11-23 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3202226A1 (en) 2020-11-20 2022-05-27 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2023288017A2 (en) * 2021-07-14 2023-01-19 Janssen Biotech, Inc. Bicyclic peptide inhibitors of interleukin-23 receptor
WO2023099669A1 (en) 2021-12-01 2023-06-08 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2023172648A2 (en) * 2022-03-09 2023-09-14 Glympse Bio, Inc. Fluorogenic substrates for aminopeptidase detection in biofluids
CN114751962B (en) * 2022-03-17 2023-11-07 北京大学 Staple peptide, preparation method and pharmaceutical application thereof
WO2024003313A1 (en) 2022-06-30 2024-01-04 Sanofi New peptides as selective il-23 receptor antagonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166514A1 (en) * 1996-11-12 2003-09-04 Jones Terence R. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US20100190710A1 (en) * 2007-07-06 2010-07-29 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
US20130172272A1 (en) * 2011-06-14 2013-07-04 Medical Diagnostic Laboratories Novel Polypeptides That Bound to IL-23 Receptor and Inhibit Binding of IL-23 and Cell Signaling Thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2111414B1 (en) 2007-02-15 2014-07-02 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US9523073B2 (en) * 2010-03-31 2016-12-20 Medical Diagnostic Laboratories, Llc Elisa for a naturally-occurring soluble truncated form of IL-23 receptor
US8946150B2 (en) * 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
CA2926685A1 (en) * 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
CA2955460A1 (en) * 2014-07-17 2016-01-21 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166514A1 (en) * 1996-11-12 2003-09-04 Jones Terence R. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US20100190710A1 (en) * 2007-07-06 2010-07-29 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
US20130172272A1 (en) * 2011-06-14 2013-07-04 Medical Diagnostic Laboratories Novel Polypeptides That Bound to IL-23 Receptor and Inhibit Binding of IL-23 and Cell Signaling Thereof

Also Published As

Publication number Publication date
EA201890325A1 (en) 2018-06-29
KR20180030663A (en) 2018-03-23
HK1259149A1 (en) 2019-11-29
CA2991984A1 (en) 2017-01-19
EP3341011A2 (en) 2018-07-04
SG10201912066SA (en) 2020-02-27
AU2016293619A1 (en) 2018-02-01
ECSP18002929A (en) 2018-03-31
CN108348580A (en) 2018-07-31
NI201800008A (en) 2018-06-29
SV2018005614A (en) 2018-05-22
WO2017011820A2 (en) 2017-01-19
PH12018500086A1 (en) 2018-07-30
KR102513978B1 (en) 2023-03-27
IL256827A (en) 2018-03-29
CN108348580B (en) 2022-05-10
CO2018000349A2 (en) 2018-07-10
CL2021000343A1 (en) 2021-08-06
AU2016293619B2 (en) 2021-02-25
HK1257747A1 (en) 2019-10-25
EA035733B9 (en) 2021-01-14
JP6858174B2 (en) 2021-04-14
CR20180029A (en) 2018-06-05
CL2018000128A1 (en) 2018-06-15
JP2018522008A (en) 2018-08-09
DOP2018000010A (en) 2018-03-30
PE20180571A1 (en) 2018-04-04
MX2018000542A (en) 2018-06-27
CL2018003322A1 (en) 2019-01-18
UA123772C2 (en) 2021-06-02
EA035733B1 (en) 2020-07-31
EP3341011A4 (en) 2019-02-20
BR112018000691A2 (en) 2018-09-18

Similar Documents

Publication Publication Date Title
WO2017011820A3 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017098328A8 (en) Therapeutic inhibitory compounds
WO2016011306A3 (en) Terminal modifications of polynucleotides
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
WO2015168532A3 (en) Compositions and methods for modulating pkk expression
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
WO2016100162A3 (en) 5,5-bicyclic oxazole orexin receptor antagonists
WO2016100157A3 (en) 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
MX2022000397A (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases.
WO2016098079A3 (en) Compositions and methods for antibodies targeting bmp6
WO2016044463A3 (en) Mk2 inhibitors and uses thereof
WO2015120062A8 (en) Therapeutic compounds and compositions
GB201506894D0 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2015200790A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
MX2017009417A (en) Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof.
WO2017136450A3 (en) Compounds and methods of treating rna-mediated diseases
EP3256438A4 (en) Compounds, compositions, and methods for the treatment of inflammatory, degenerative, and neurodegenerative diseases
WO2018226992A8 (en) Tau aggregation inhibitors
ZA202002166B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3223809A4 (en) Amino acid compositions for the treatment of symptoms of disease
PH12017500114A1 (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
IL270927B (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
EA201791937A1 (en) ANTI-INFLAMMATORY POLYPEPTIDES

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16825301

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 11201710859R

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 2991984

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12018500086

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 256827

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2018-000008 I

Country of ref document: NI

Ref document number: 000053-2018

Country of ref document: PE

ENP Entry into the national phase

Ref document number: 2018501178

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/000542

Country of ref document: MX

Ref document number: CR2018-000029

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: NC2018/0000349

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2016293619

Country of ref document: AU

Date of ref document: 20160715

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20187004612

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201801482

Country of ref document: UA

Ref document number: 2016825301

Country of ref document: EP

Ref document number: 201890325

Country of ref document: EA

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16825301

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018000691

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112018000691

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180112